Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Considers 24-Hour Deadline for Recall of Seriously Harmful Drugs (China)

This article was originally published in PharmAsia News

Executive Summary

In the wake of major recalls for two leukemia drugs, China's State Food and Drug Administration is drafting new rules for pharmaceutical manufacturers who suspect there may be a problem with their products. Under the new plan, recalled drugs would be grouped into three categories. In the first category are drugs that could have deadly or permanent effects. These drugs must be recalled within 24 hours. The second category includes drugs that could cause temporary damage and must be recalled within three days. The third category is reserved for labeling mistakes or other minor issues. Manufacturers would have seven days to enact these kinds of recalls. Chinese officials are still finalizing consequences for pharmaceutical companies found violating these rules. Proposed punishments include fines up to 50,000 yuan or the revocation of the company's production license. (Click here for more

You may also be interested in...

Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Biden COVID-19 Plan Would Grow Domestic Manufacturing Base

The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.

People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts